Study directory

ADHD studies

Compare studies and check their requirements with the research team.

Back to overview
More filters: keywords, city, remote
1740studies shown
Showing 1,405-1,416 of 1,740
Drug study icon
CompletedEUCTR 2008-001767-11

A Randomized, Controlled, Open-Label Comparison Study of the Efficacy and Safety of Slow Transitioning compared with Fast Transitioning from a Stimulant Medication to Atomoxetine in Pediatric and A...

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Portugal
Why is this study shown?

This study is directly about ADHD.

ADHDDrugA study involving a medication or substance.
Countries
United Kingdom, Portugal, Spain
Sponsor
Eli Lilly and Company Limited
Condition
ADHD
Drug study icon
CompletedEUCTR 2006-002716-94

AD/HD diagnosis through EEG, a pilot study

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Iceland
Why is this study shown?

This study is directly about ADHD.

ADHDDrug
Countries
Iceland
Sponsor
Mentis Cura ehf.
Condition
ADHD
Drug study icon
CompletedEUCTR 2006-001470-25

Randomisierte, doppelblinde Studie zum Vergleich neuropsychologischer Effekte von Atomoxetin gegen Placebo im Tagesverlauf bei Kindern mit Aufmerksamkeitsdefizit-/Hyperaktivitätsstörung unter Anwen...

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Germany
Why is this study shown?

This study is directly about ADHD.

ADHDDrug
Countries
Germany
Sponsor
Lilly Deutschland GmbH, Teichweg 3, 35396 Gießen
Condition
ADHD
Drug study icon
Recruitment unclearEUCTR 2006-005512-27

A Randomized, Controlled, Open-Label Study of the Long-Term Impact on Functioning using Atomoxetine Hydrochloride Compared to Other Early Standard Care in the Treatment of Attention-Deficit/Hyperac...

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Belgium
Why is this study shown?

This study is directly about ADHD.

ADHDDrug
Countries
France, United Kingdom, Belgium, ...
Sponsor
Eli Lilly and Company
Condition
ADHD
Drug study icon
Recruitment unclearEUCTR 2016-002875-81

Bumetanide for the Autism Spectrum Clinical Effectiveness Trial

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Netherlands
Why is this study shown?

This study is directly about ADHD.

ADHDDrug
Countries
Netherlands
Sponsor
UMC Utrecht
Condition
ADHD
Drug study icon
Recruitment unclearEUCTR 2020-003660-11

Do effects of methylphenidate decline after long-term use? A double-blind, placebo-controlled cross-over study of effects of methylphenidate on cognitive functioning and real world behavior in trea...

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Netherlands
Why is this study shown?

This study is directly about ADHD.

ADHDDrug
Countries
Netherlands
Sponsor
Accare
Condition
ADHD
Drug study icon
Recruitment unclearEUCTR 2020-002196-35

post-trial access cohort BUmetanide for Developmental DIsorders

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Netherlands
Why is this study shown?

This study is directly about ADHD.

ADHDDrug
Countries
Netherlands
Sponsor
Amsterdam UMC, location VUmc
Condition
ADHD
Drug study icon
Not recruitingEUCTR 2010-018579-12

A Phase 3, Randomised, Double-blind, Multicentre, Parallel-group, Placebo- and Active-reference, Dose-optimisation Efficacy and Safety Study of Extended-release Guanfacine Hydrochloride in Children...

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Austria
Why is this study shown?

This study is directly about ADHD.

ADHDDrug
Countries
France, United Kingdom, Austria, ...
Sponsor
Shire Pharmaceutical Development Ltd
Condition
ADHD
Drug study icon
Not recruitingEUCTR 2018-000821-29

A Phase 4, Multicenter, 2-part Study Composed of a 1-Year Randomized, Double-blind, Parallel-group, Placebo-controlled, Active-comparator, Dose-optimization Evaluation followed by a 1-Year Open-lab...

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

Multiple locations, including Leuven
Why is this study shown?

This study is directly about ADHD.

ADHDDrug
Countries
Belgium, Germany, Netherlands, ...
Sponsor
Takeda Development Center Americas, Inc.
Condition
ADHD
Behavioral study icon
Not recruitingISRCTN13915109

Computer Enabled Neuroplasticity Treatment (CENT)

This study is looking at a support or therapy approach for people with Attention Deficit/Hyperactivity Disorder, Mental and Behavioural Disorders, or Disturbance of activity and attention. Participants take part in the program or support approach and complete follow-up assessments.

In Finland
Why is this study shown?

This study is directly about ADHD.

ADHDOther
Countries
Finland
Sponsor
University of Helsinki
Condition
ADHD
Data coverage

Public registry coverage is progressing

HopeStage gathers information about mental health clinical trials from the public registries we currently index. We are progressively improving registry coverage, but this does not mean that every study in the world is already included.